Evommune, Inc. (EVMN) earnings date
Mar 4, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 35% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 43 days, typically, give or take 16 (last 5 releases) |
Last 5 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 12, 2026 | after close | 43 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | after close | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | after close | 37 | 8-K |
| Q4 FY2025 | Thu, Mar 5, 2026 | after close | 64 | 8-K |
| Q3 FY2025 | Thu, Dec 11, 2025 | after close | 72 | 8-K |
What they guided beta
| Q3 FY2026 | "Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights Expanded pipeline with in-licensing of EVO570, a potential best-in-class oral VAV-1 molecular glue degrader EVO301 late-breaking EADV data demonstrate clear therapeutic signal and favorable safety and tolerability profile, supporting Phase 2b trial in AD expected for mid-2027 initiation Additional clinical milestones expected in 2027, including initiation of the EVO570 Phase 1 trial in early 2027, the EVO301 Phase 2 trial in ulcerative colitis and the EVO646 Phase 1 study Key 2027 data expected to include P" exhibit |
| Q3 FY2026 | "“As we advance EVO301 into Phase 2b and expand into ulcerative colitis, 2027 will be a year of execution and clinical catalysts for Evommune, with additional new clinical studies across EVO646 and EVO570 and Phase 2b migraine top-line data expected from EVO756." exhibit |
| Q3 FY2026 | "Global Phase 2b AD Trial Expected to Initiate in Mid-2027: Evommune continues to advance EVO301 toward the initiation of a Phase 2b dose-ranging trial in approximately 200 adults with moderate-to-severe AD." exhibit |
| Q3 FY2026 | "Phase 2 Proof-of-Concept Trial in Ulcerative Colitis (UC) Planned to Initiate in First Quarter of 2027, Data Expected in 2028: Evommune plans to initiate a Phase 2 proof-of-concept trial of EVO301 in UC in the first quarter of 2027, extending development beyond dermatology to inflammatory bowel disease, where IL-18 and IL-22 are upregulated." exhibit |
| Q3 FY2026 | "Top-Line Data from Phase 2b Migraine Trial Anticipated in Second Half of 2027: The Phase 2b dose-ranging trial of EVO756 in adults with refractory migraine is underway, with top-line data expected in the second half of 2027." exhibit |
| Q2 FY2026 | "Phase 2b Top-Line Data Readout in AD Expected Next Month: The Company expects to report top-line data in September 2026 for the fully-enrolled Phase 2b dose-ranging clinical trial (N=120) in moderate-to-severe AD patients." exhibit |
| Q2 FY2026 | "Top-line data from the trial are expected in 2027." exhibit |
| Q2 FY2026 | "Phase 2b AD Trial to Initiate in mid-2027: The planned Phase 2b, placebo-controlled, dose-ranging clinical trial is expected to include at least three subcutaneous dosing regimens of EVO301 tested over a 16-week treatment period." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/EVMN
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/EVMN
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/EVMN/"><img src="https://veritasdata.dev/embed/EVMN.svg" alt="EVMN earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/EVMN/)
Script
<script async src="https://veritasdata.dev/embed/EVMN.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/EVMN"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.